转移性结直肠癌治疗的现状与未来：新候选靶点综述
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.
作者信息
Martini Giulia, Troiani Teresa, Cardone Claudia, Vitiello Pietropaolo, Sforza Vincenzo, Ciardiello Davide, Napolitano Stefania, Della Corte Carminia Maria, Morgillo Floriana, Raucci Antonio, Cuomo Antonio, Selvaggi Francesco, Ciardiello Fortunato, Martinelli Erika
机构信息
Giulia Martini, Teresa Troiani, Claudia Cardone, Pietropaolo Vitiello, Vincenzo Sforza, Davide Ciardiello, Stefania Napolitano, Carminia Maria Della Corte, Floriana Morgillo, Fortunato Ciardiello, Erika Martinelli, Department of Internal and Experimental Medicine "F. Magrassi e A. Lanzara", Institute of Medical Oncology, Università degli studi della Campania Luigi Vanvitelli, 80131 Naples, Italy.
出版信息
World J Gastroenterol. 2017 Jul 14;23(26):4675-4688. doi: 10.3748/wjg.v23.i26.4675.
In the last two decades, great efforts have been made in the treatment of metastatic colorectal cancer (mCRC) due to the approval of new target agents for cytotoxic drugs. Unfortunately, a large percentage of patients present with metastasis at the time of diagnosis or relapse after a few months. The complex molecular heterogeneity of this disease is not completely understood; to date, there is a lack of predictive biomarkers that can be used to select subsets of patients who may respond to target drugs. Only the -mutation status is used to predict resistance to anti-epidermal growth factor receptor agents in patients with mCRC. In this review, we describe approved targeted therapies for the management of metastatic mCRC and discuss new candidate targets on the horizon.
在过去二十年中，由于新型靶向药物获批用于细胞毒性药物治疗转移性结直肠癌（mCRC），人们付出了巨大努力。不幸的是，很大一部分患者在诊断时就已出现转移，或者在几个月后复发。这种疾病复杂的分子异质性尚未完全明了；迄今为止，缺乏可用于选择可能对靶向药物有反应的患者亚组的预测性生物标志物。在mCRC患者中，仅使用 -突变状态来预测对抗表皮生长因子受体药物的耐药性。在本综述中，我们描述了已获批用于转移性mCRC治疗的靶向疗法，并讨论了即将出现的新候选靶点。
Zotero 插件